Prognostic Study of Prostate Cancer Via Dynamic Change of PSA in Peritoneal Drainage Fluid After Radical Prostatectomy

NCT06608225 · tracked via the Priya Life Science China tracker

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase

Observational

Started

2024-12-01

Last updated

2024-11-29

Condition(s) studied

Prostatic NeoplasmsProstate-Specific Antigen

Study summary

This study investigates the prognostic value of dynamic changes in Prostate-Specific Antigen (PSA) levels found in the peritoneal drainage fluid after radical prostatectomy. Prostate cancer is one of the most common cancers in men, and radical prostatectomy is a standard treatment. While PSA levels in the blood are commonly used as a marker for diagnosis, this study focuses on the significance of PSA levels in the prognosis of prostate cancer. The findings may provide insights into improved post-surgical monitoring and more tailored therapeutic strategies for prostate cancer patients.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: * Prostate cancer patients treated with radical prostatectomy Exclusion Criteria: * 1\. Received neoadjuvant endocrine/chemotherapy before surgery; * 2\. Urine leakage after surgery (positive creatinine test of drainage fluid).

Primary outcome measure(s)

PSA Levels in Drainage Fluid — Measured daily for up to 3 days post-surgery.
Postoperative Prostate-Specific Antigen (PSA) Levels in The Peritoneal Drainage Fluid

Trial sites (1)

Facility	City	Region	Status
Shanghai General Hospital	Shanghai	Shanghai Municipality

More Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine trials in China

Evaluation of Vulnerability of Carotid Plaques and Prediction of Cardio-Cerebrovascular Event Using Ultrasonic Imaging Recruiting

Correlation Of EUS-SWQ And Liver Fibrosis Pathology In Chronic Liver Disease Recruiting

6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors Starting soon

Safety, Tolerability, and Accuracy of a Hydrogel-Based Wearable Dynamic Intraocular Pressure Sensor in Healthy Adults Starting soon

Subthalamic Nucleus-Targeted Transcranial Temporal Interference Stimulation for Motor and Non-Motor Symptoms in Parkinson's Disease Recruiting

Other trials for the same condition

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer Recruiting

A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer Active, not recruiting

A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. Starting soon

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) Recruiting

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06608225 on ClinicalTrials.gov ↗ ← All trials in China